Autolus Therapeutics plc (AUTL) stock
AUTLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/3019% below fair value
$1.14−0.03 (-2.56%)
Close on Nov 16, 2026Market cap $303.43MP/E –Yield –
Autolus Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Autolus Therapeutics's ebitda for the twelve months ending Jun 30, 2026 was -$238.85M. For fiscal 2025 it was -$262.25M. The highest annual figure on record is -$132.59M in fiscal 2021.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$262.25M | – |
| FY2024 | Dec 31, 2024 | -$233.87M | – |
| FY2023 | Dec 31, 2023 | -$173.14M | – |
| FY2022 | Dec 31, 2022 | -$135.99M | – |
| FY2021 | Dec 31, 2021 | -$132.59M | – |
| FY2020 | Dec 31, 2020 | -$162.49M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | -$41.68M | – |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | -$57.30M | – |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | -$70.32M | – |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | -$69.54M | – |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | -$59.13M | – |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | -$63.25M | – |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | -$73.95M | – |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | -$65.94M | – |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | -$57.03M | – |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | -$36.95M | – |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | -$51.50M | – |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | -$41.53M | – |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | -$42.87M | – |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | -$37.25M | – |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | -$10.00M | – |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | -$38.21M | – |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | -$45.67M | – |
| Q3 FY2020CQ3 2020 | Sep 30, 2020 | -$41.24M | – |
| Q2 FY2020CQ2 2020 | Jun 30, 2020 | -$38.28M | – |
| Q1 FY2020CQ1 2020 | Mar 31, 2020 | -$37.30M | – |
See a number that looks wrong?